Rifampin isoniazid: Difference between revisions

Revision as of 02:30, 5 January 2014

FDA Package Insert (RIFAMATE^®)
Rifampin isoniazid
Description
Clinical Pharmacology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Overview

Rifampicin was introduced in 1967,^[1] as a major addition to the cocktail-drug treatment of tuberculosis and inactive meningitis, along with pyrazinamide, isoniazid, ethambutol and streptomycin ("PIERS"). It requires a prescription in North America. It must be administered regularly daily for several months without break; otherwise, the risk of drug-resistant tuberculosis is greatly increased.^[1] In fact, this is the primary reason it is used in tandem with the three aforementioned drugs, particularly isoniazid.^[2] This is also the primary motivation behind directly observed therapy for tuberculosis.

US Brand Names

RIFAMATE^®

FDA Package Insert

Mechanisms of Action

References

↑ ^1.0 ^1.1 Long, James W. (1991). Essential Guide to Prescription Drugs 1992. New York: HarperCollins Publishers. pp. 925–929. ISBN 0-06-273090-8.
↑ Erlich, Henry, W Ford Doolittle, Volker Neuhoff, and et al. . Molecular Biology of Rifomycin. New York, NY: MSS Information Corporation, 1973. pp. 44-45, 66-75, 124-130.

[isbn0-06-273090-8-1] 1.0 ^1.1 Long, James W. (1991). Essential Guide to Prescription Drugs 1992. New York: HarperCollins Publishers. pp. 925–929. ISBN 0-06-273090-8.

[Erlich-2] Erlich, Henry, W Ford Doolittle, Volker Neuhoff, and et al. . Molecular Biology of Rifomycin. New York, NY: MSS Information Corporation, 1973. pp. 44-45, 66-75, 124-130.

[1]

[2]

@@ Line 5: / Line 5: @@
 ==Overview==
-''Rifampicin''' ([[International Nonproprietary Name|INN]]) {{IPAc-en|r|ɪ|ˈ|f|æ|m|p|ə|s|ɪ|n}} or '''rifampin''' ([[United States Adopted Name|USAN]]) is a [[bactericidal]] [[antibiotic]] drug of the [[rifamycin]] group.<ref name="isbn0-07-142290-0">{{cite book |author=Masters, Susan B.; Trevor, Anthony J.; Katzung, Bertram G. |title=Katzung & Trevor's pharmacology |publisher=Lange Medical Books/McGraw Hill, Medical Pub. Division |location=New York |year=2005 |pages= |isbn=0-07-142290-0 |oclc= |doi= |accessdate=}}</ref>
+Rifampicin was introduced in 1967,<ref name="isbn0-06-273090-8">{{cite book |author=Long, James W. |title=Essential Guide to Prescription Drugs 1992 |publisher=HarperCollins Publishers |location=New York |year=1991 |pages=925–929 |isbn=0-06-273090-8 |oclc= |doi= |accessdate=}}</ref> as a major addition to the cocktail-drug treatment of [[tuberculosis]] and inactive [[meningitis]], along with [[pyrazinamide]], [[isoniazid]], [[ethambutol]] and [[streptomycin]] ("PIERS"). It requires a prescription in North America. It must be administered regularly daily for several months without break; otherwise, the risk of drug-resistant tuberculosis is greatly increased.<ref name="isbn0-06-273090-8" /> In fact, this is the primary reason it is used in tandem with the three aforementioned drugs, particularly isoniazid.<ref name="Erlich">Erlich, Henry, W Ford Doolittle, Volker Neuhoff, and et al. . Molecular Biology of Rifomycin. New York, NY: MSS Information Corporation, 1973. pp. 44-45, 66-75, 124-130.</ref> This is also the primary motivation behind directly observed therapy for tuberculosis.
-Rifampicin inhibits bacterial DNA-dependent RNA synthesis by inhibiting bacterial DNA-dependent [[RNA polymerase]].<ref name="Calvori"
-It is a semisynthetic compound derived from ''Amycolatopsis rifamycinica '' (formerly known as ''Amycolatopsis mediterranei'' and ''Streptomyces mediterranei'').<ref>{{cite journal|author=Sensi P, Margalith P, Timbal MT|title=Rifomycin, a new antibiotic—preliminary report|journal=Farmaco Ed Sci|year=1959|volume=14|pages=146–147}}</ref>  Rifampicin may be abbreviated '''R''', '''RMP''', '''RA''', '''RF''', or '''RIF''' (US
 ==Category==